Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.

Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q1 2021 Results - Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 14.89% and 4.93%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Q1 Earnings and Revenues Surpass Estimates

Edwards Lifesciences on Tuesday reported adjusted earnings of 54 cents per share on $1.22 billion in sales for the first quarter ended March 31. In response, EW stock jumped.

Edwards Lifesciences Adds To Breakout After Smashing First-Quarter Estimates

Shares of Edwards Lifesciences (NYSE:EW) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 64.24% year over year to $0.54, which beat the estimate of $0.47.

Edwards Lifesciences: Q1 Earnings Insights

Edwards Lifesciences (NYSE:EW) releases its next round of earnings this Tuesday, April 20. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.

Edwards Lifesciences's Earnings Outlook

Advanced Micro Devices

Boston Scientific

Intel

NVIDIA

American Eagle Outfitters

Cheesecake Factory

Cracker Barrel Old Country Store

With the trading day about halfway over, the broad markets were pushing much higher with solid gains across the board.

AMD, Boston Scientific, Intel, Nvidia and More Thursday Afternoon Analyst Calls

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for

IRVINE, Calif., April 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2021 after the market closes on Tuesday, April 20, 2021, and will host a conference call at 5:30 p.m.

Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021

Edwards Lifesciences has shown consistent earnings and revenue growth in the last few years and it has strong profitability measurements. The company is scheduled to report first quarter earnings results on April 20 with earnings expected to decline slightly from Q1 2020.

Guidance Will Be Key When Edwards Lifesciences Reports Q1 Earnings

Apple

Chevron

JPMorgan Chase & Co

Verizon

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway Inc. (NYSE:BRK.A)(NYSE:BRK.B) disclosed on Tuesday its fourth-quarter 2020 portfolio, revealing new holdings in Verizon Inc. (NYSE:VZ), Chevron Corp. (NYSE:CVX) and The E.W. Scripps Co. (NYSE:EW).

Warren Buffett's Berkshire Reveals 4th-Quarter Trades

AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards' bioprosthetic surgical aortic valve with the company's novel RESILIA tissue platform show favorable safety and hemodynamic...

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q4 2020 Results - Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -5.66% and 0.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Q4 Earnings Lag Estimates

Shares of Edwards Lifesciences (NYSE:EW) decreased 4.5% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 65.75% over the past year to $0.50, which missed the estimate of $0.53.

Recap: Edwards Lifesciences Q4 Earnings

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

What's in Store for Edwards Lifesciences in (EW) Q4 Earnings?

IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesday, January 27, 2021, and will host a conference call at 5:00 p.m. ET that day to discuss those...

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021

Edwards Lifesciences is a quality name that sits at the tip of the spear in cardiovascular value procedure offerings. The company has remained resilient in the face of the pandemic, and is well positioned to benefit from the rebound in procedure deferrals.

Edwards Lifesciences: TAVR, Mitral And Tricuspid Segments Are Each Meaningful Compounders

IRVINE, Calif., Dec. 21, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW), today announced that the first patient has been treated in the RESTORE clinical trial, which will evaluate the safety and effectiveness of the investigational HARPOON Beating Heart Mitral Valve Repair System in...

Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease

CNH Industrial NV

Hasbro

Microsoft

NextEra Energy

Owens Corning

Prologis

ESG investing can help create value both for society and shareholders. These seven ESG stocks are a good place to start.

7 ESG Investing Ideas That Could Add to Your Wallet and to Your Soul

If you are looking for the best ideas for your portfolio you may want to consider some of Wedgewood Partners top stock picks. Wedgewood Partners, an investment management firm, is bullish on Edwards Lifesciences Corp (NYSE:EW) stock. In its Q3 2019 investor letter – you can download a copy here – the firm discussed its investment thesis on Edwards Lifesciences Corp (NYSE:EW) stock. Edwards Lifesciences Corp (NYSE:EW) is a medical technology company.

Lookback: Wedgewood Partners 2019 Edwards Lifesciences Corp (EW) Thesis

Franco-Nevada C

Masimo

There are many useful nooks and crannies on the GuruFocus website, including screeners that help us find stocks outside the mainstream.

3 Strong, Margin-Expanding Stocks

Strong Q3 exit with +6.4% growth in TAVR therapy sales, in spite of pressures from COVID-19. Shareholders have enjoyed +70% gains since March, however, with high volatility to the downside, which needs to be priced into the valuation.

Edwards Lifesciences Research Update: Dislocation In Valuation Remains

In this article we will take a look at whether hedge funds think Edwards Lifesciences Corporation (NYSE:EW) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks historically outperformed the market after adjusting for known risk factors.

Were Hedge Funds Wrong About Edwards Lifesciences Corporation (EW)?

Edwards expects to resume double digit growth as a robust product pipeline gets to market

News for Edwards Lifesciences Stock (EW)